BIAF vs. AIKI, SNCE, CCLD, NRBO, MHUA, TLPH, CALC, NTRB, NRSN, and XLO
Should you be buying bioAffinity Technologies stock or one of its competitors? The main competitors of bioAffinity Technologies include AIkido Pharma (AIKI), Science 37 (SNCE), CareCloud (CCLD), NeuroBo Pharmaceuticals (NRBO), Meihua International Medical Technologies (MHUA), Talphera (TLPH), CalciMedica (CALC), Nutriband (NTRB), NeuroSense Therapeutics (NRSN), and Xilio Therapeutics (XLO). These companies are all part of the "medical" sector.
bioAffinity Technologies (NASDAQ:BIAF) and AIkido Pharma (NASDAQ:AIKI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, community ranking, risk, valuation and dividends.
1.6% of bioAffinity Technologies shares are held by institutional investors. Comparatively, 10.9% of AIkido Pharma shares are held by institutional investors. 44.3% of bioAffinity Technologies shares are held by company insiders. Comparatively, 8.6% of AIkido Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
In the previous week, bioAffinity Technologies had 2 more articles in the media than AIkido Pharma. MarketBeat recorded 2 mentions for bioAffinity Technologies and 0 mentions for AIkido Pharma. bioAffinity Technologies' average media sentiment score of 0.44 beat AIkido Pharma's score of 0.00 indicating that bioAffinity Technologies is being referred to more favorably in the media.
bioAffinity Technologies has a beta of 3.98, suggesting that its stock price is 298% more volatile than the S&P 500. Comparatively, AIkido Pharma has a beta of 0.93, suggesting that its stock price is 7% less volatile than the S&P 500.
AIkido Pharma has a net margin of 0.00% compared to bioAffinity Technologies' net margin of -2,244.15%. AIkido Pharma's return on equity of -18.21% beat bioAffinity Technologies' return on equity.
AIkido Pharma received 101 more outperform votes than bioAffinity Technologies when rated by MarketBeat users.
AIkido Pharma has higher revenue and earnings than bioAffinity Technologies.
Summary
AIkido Pharma beats bioAffinity Technologies on 7 of the 11 factors compared between the two stocks.
Get bioAffinity Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for BIAF and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BIAF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
bioAffinity Technologies Competitors List
Related Companies and Tools